Download PDF
Klin Monbl Augenheilkd 2019; 236(09): 1091-1095
DOI: 10.1055/a-0898-3965
Übersicht
Georg Thieme Verlag KG Stuttgart · New York

Physikalische Therapie der nicht exsudativen altersabhängigen Makuladegeneration

Physical Therapy of Non-Exudative Age-Related Macular Degeneration
Jost Lennart Lauermann
Klinik für Augenheilkunde, Universitätsklinikum Münster
,
Nicole Eter
Klinik für Augenheilkunde, Universitätsklinikum Münster
,
Florian Alten
Klinik für Augenheilkunde, Universitätsklinikum Münster
› Author Affiliations
Further Information

Publication History

eingereicht 24 March 2019

akzeptiert 01 April 2019

Publication Date:
19 June 2019 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Trotz des Erfolgs der Anti-VEGF-Therapien (VEGF: vascular endothelial growth factor) bei der neovaskulären altersabhängigen Makuladegeneration (AMD) im zurückliegenden Jahrzehnt gibt es zahlreiche noch ungelöste Herausforderungen in der AMD-Therapie. Um Patientengesundheit zu verbessern und Gesundheitssysteme zu entlasten, erscheint die Entwicklung neuer Interventionsmöglichkeiten von großer Wichtigkeit, die bereits die Progression einer AMD-Frühform in eine Spätform verhindern oder verzögern können. Im Bereich der physikalischen Behandlungsansätze der nicht exsudativen AMD gibt es bis dato kein anerkanntes Therapieverfahren. Es erscheint gegenwärtig sinnvoll, die Forschungsbemühungen im Bereich der intraokularen Blaufilterlinsen und der Subthreshold-Laserbehandlung im Rahmen prospektiver Studien weiterzuverfolgen. Der folgende Artikel soll eine Übersicht über die aktuellen Strategien einer physikalischen Therapie der nicht exsudativen AMD geben.

Abstract

Despite the success of anti-VEGF therapy (VEGF: vascular endothelial growth factor) in neovascular age-related macular degeneration (AMD) in the last decade, many unmet needs in AMD management remain. In order to improve patient eye health and relieve the burden on health systems, the development of new intervention options appears to be of great importance if they can delay or even prevent the progression of an early form into a late form. In the field of physical treatment for non-exudative AMD, there is no recognised therapy procedure to date. It now appears appropriate to pursue further research efforts in the field of intraocular blue filter lenses and subthreshold laser treatment in prospective studies. The following article provides an overview of the current strategies of physical therapy for non-exudative AMD.

Schlüsselwörter

altersabhängige Makuladegeneration - Drusen - physikalische Therapie

Key words

age-related macular degeneration - drusen - physical therapy
 

  • Literatur

  • 1 Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol 2012; 153: 209-213.e2
    CrossrefPubMedGoogle Scholar
  • 2 Borooah S, Jeganathan VS, Ambrecht AM. et al. Long-term visual outcomes of intravitreal ranibizumab treatment for wet age-related macular degeneration and effect on blindness rates in south-east Scotland. Eye (Lond) 2015; 29: 1156-1161
    CrossrefPubMedGoogle Scholar
  • 3 Hara C, Wakabayashi T, Toyama H. et al. Characteristics of patients with neovascular age-related macular degeneration who are non-responders to intravitreal aflibercept. Br J Ophthalmol 2018; DOI: 10.1136/bjophthalmol-2018-312275.
    CrossrefPubMedGoogle Scholar
  • 4 Cruess AF, Zlateva G, Xu X. et al. Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study. Pharmacoeconomics 2008; 26: 57-73
    CrossrefPubMedGoogle Scholar
  • 5 Holz FG, Strauss EC, Schmitz-Valckenberg S. et al. Geographic atrophy: clinical features and potential therapeutic approaches. Ophthalmology 2014; 121: 1079-1091
    CrossrefPubMedGoogle Scholar
  • 6 The Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 2013; 309: 2005-2015
    CrossrefPubMedGoogle Scholar
  • 7 Meyers KJ, Liu Z, Millen AE. et al. Joint associations of diet, lifestyle, and genes with age-related macular degeneration. Ophthalmology 2015; 122: 2286-2294
    CrossrefPubMedGoogle Scholar
  • 8 Frennesson C, Nilsson SE. Prophylactic laser treatment in early age related maculopathy reduced the incidence of exudative complications. Br J Ophthalmol 1998; 82: 1169-1174
    CrossrefPubMedGoogle Scholar
  • 9 Gass JD. Photocoagulation of macular lesions. Trans Am Acad Ophthalmol Otolaryngol 1971; 75: 580-608
    PubMedGoogle Scholar
  • 10 Sigelman J. Foveal drusen resorption one year after perifoveal laser photocoagulation. Ophthalmology 1991; 98: 1379-1383
    CrossrefPubMedGoogle Scholar
  • 11 Wetzig PC. Treatment of drusen-related aging macular degeneration by photocoagulation. Trans Am Ophthalmol Soc 1988; 86: 276-290
    PubMedGoogle Scholar
  • 12 Choroidal Neovascularization Prevention Trial Research Group. Laser treatment in fellow eyes with large drusen: updated findings from a pilot randomized clinical trial. Ophthalmology 2003; 110: 971-978
    CrossrefPubMedGoogle Scholar
  • 13 Owens SL, Bunce C, Brannon AJ. et al. Prophylactic laser treatment hastens choroidal neovascularization in unilateral age-related maculopathy: final results of the drusen laser study. Am J Ophthalmol 2006; 141: 276-281
    CrossrefPubMedGoogle Scholar
  • 14 Complications of Age-Related Macular Degeneration Prevention Trial Research Group. Laser treatment in patients with bilateral large drusen: the complications of age-related macular degeneration prevention trial. Ophthalmology 2006; 113: 1974-1986
    CrossrefPubMedGoogle Scholar
  • 15 Virgili G, Michelessi M, Parodi MB. et al. Laser treatment of drusen to prevent progression to advanced age-related macular degeneration. Cochrane Database Syst Rev 2015; (10) CD006537
    PubMedGoogle Scholar
  • 16 Guymer RH, Wu Z, Hodgson LAB. et al. Subthreshold nanosecond laser intervention in age-related macular degeneration: The LEAD randomized controlled clinical trial. Ophthalmology 2018; DOI: 10.1016/j.ophtha.2018.09.015.
    CrossrefPubMedGoogle Scholar
  • 17 Brinkmann R, Schule G, Neumann J. et al. [Selective retina therapy: methods, technique, and online dosimetry]. Ophthalmologe 2006; 103: 839-849
    CrossrefPubMedGoogle Scholar
  • 18 Framme C, Schuele G, Roider J. et al. Influence of pulse duration and pulse number in selective RPE laser treatment. Lasers Surg Med 2004; 34: 206-215
    CrossrefPubMedGoogle Scholar
  • 19 Roider J, Hillenkamp F, Flotte T. et al. Microphotocoagulation: selective effects of repetitive short laser pulses. Proc Natl Acad Sci U S A 1993; 90: 8643-8647
    CrossrefPubMedGoogle Scholar
  • 20 Zhang JJ, Sun Y, Hussain AA. et al. Laser-mediated activation of human retinal pigment epithelial cells and concomitant release of matrix metalloproteinases. Invest Ophthalmol Vis Sci 2012; 53: 2928-2937
    CrossrefPubMedGoogle Scholar
  • 21 Jobling A, Guymer R, Vessey K. et al. Nanosecond laser therapy reverses pathologic and molecular changes in age-related macular degeneration without retinal damage. FASEB J 2014; 29: 696-710
    PubMedGoogle Scholar
  • 22 Guymer RH, Brassington KH, Dimitrov P. et al. Nanosecond-laser application in intermediate AMD: 12-month results of fundus appearance and macular function. Clin Exp Ophthalmol 2014; 42: 466-479
    CrossrefPubMedGoogle Scholar
  • 23 Wu Z, Luu CD, Ayton LN. et al. Optical coherence tomography-defined changes preceding the development of drusen-associated atrophy in age-related macular degeneration. Ophthalmology 2014; 121: 2415-2422
    CrossrefPubMedGoogle Scholar
  • 24 Alten F, Eter N. Current knowledge on reticular pseudodrusen in age-related macular degeneration. Br J Ophthalmol 2015; 99: 717-722
    CrossrefPubMedGoogle Scholar
  • 25 Alten F, Clemens CR, Heiduschka P. et al. Characterisation of reticular pseudodrusen and their central target aspect in multi-spectral, confocal scanning laser ophthalmoscopy. Graefes Arch Clin Exp Ophthalmol 2014; 252: 715-721
    CrossrefPubMedGoogle Scholar
  • 26 Spaide RF, Ooto S, Curcio CA. Subretinal drusenoid deposits AKA pseudodrusen. Surv Ophthalmol 2018; 63: 782-815
    CrossrefPubMedGoogle Scholar
  • 27 Berufsverband der Augenärzte Deutschlands e. V. (BVA); Deutsche Ophthalmologische Gesellschaft (DOG), Retinologische Gesellschaft e. V. (RG). [Supplementary statement of the German Professional Association of Ophthalmologists (BVA), the German Ophthalmological Society (DOG) and the Retinological Society (RG) on laser treatment of drusen in age-related macular degeneration (AMD): Status October 2018]. Ophthalmologe 2018; 116: 138-143
    PubMedGoogle Scholar
  • 28 Chow AY, Chow VY, Packo KH. et al. The artificial silicon retina microchip for the treatment of vision loss from retinitis pigmentosa. Arch Ophthalmol 2004; 122: 460-469
    CrossrefPubMedGoogle Scholar
  • 29 Sehic A, Guo S, Cho KS. et al. Electrical stimulation as a means for improving vision. Am J Pathol 2016; 186: 2783-2797
    CrossrefPubMedGoogle Scholar
  • 30 Anastassiou G, Schneegans AL, Selbach M. et al. Transpalpebral electrotherapy for dry age-related macular degeneration (AMD): an exploratory trial. Restor Neurol Neurosci 2013; 31: 571-578
    PubMedGoogle Scholar
  • 31 Chaikin L, Kashiwa K, Bennet M. et al. Microcurrent stimulation in the treatment of dry and wet macular degeneration. Clin Ophthalmol 2015; 9: 2345-2353
    PubMedGoogle Scholar
  • 32 Shinoda K, Imamura Y, Matsuda S. et al. Transcutaneous electrical retinal stimulation therapy for age-related macular degeneration. Open Ophthalmol J 2008; 2: 132-136
    CrossrefPubMedGoogle Scholar
  • 33 Kondrot EC. Initial results of microcurrent stimulation in the treatment of age related macular degeneration. Townsend Lett Doct Pat 2002; 231: 65-67
    PubMedGoogle Scholar
  • 34 Kondrot EC. Improvement in vision parameters for participants treated with alternative therapies in a 3-day program. Altern Ther Health Med 2015; 21: 22-35
    PubMedGoogle Scholar
  • 35 Welte AK, Hahn U, Büssing A. et al. [Systematic review of the application of complementary and alternative medicine and their potential therapeutic benefits in the treatment of ophthalmology patients]. Klin Monatsbl Augenheilkd 2017; 234: 686-696
    Article in Thieme ConnectPubMedGoogle Scholar
  • 36 AAO Complementary Therapy Task Force. Acupuncture for age-related macular degeneration CTA – 2007 (März 2007). Im Internet: https://www.aao.org/complimentary-therapy-assessment/acupuncture-agerelated-macular-degeneration-cta-m-4 Stand: 04.03.2019
    PubMedGoogle Scholar
  • 37 Klein R, Peto T, Bird A. et al. The epidemiology of age-related macular degeneration. Am J Ophthalmol 2004; 137: 486-495
    CrossrefPubMedGoogle Scholar
  • 38 Waugh N, Loveman E, Colquitt J. et al. Treatments for dry age-related macular degeneration and Stargardt disease: a systematic review. Health Technol Assess 2018; 22: 1-168
    Google Scholar
  • 39 Sparrow JR, Cai B. Blue light-induced apoptosis of A2E-containing RPE: involvement of caspase-3 and protection by Bcl-2. Invest Ophthalmol Vis Sci 2001; 42: 1356-1362
    PubMedGoogle Scholar
  • 40 Cruickshanks KJ, Klein R, Klein BE. et al. Sunlight and the 5-year incidence of early age-related maculopathy: the Beaver Dam Eye Study. Arch Ophthalmol 2001; 119: 246-250
    PubMedGoogle Scholar
  • 41 Algvere PV, Marshall J, Seregard S. Age-related maculopathy and the impact of blue light hazard. Acta Ophthalmol Scand 2006; 84: 4-15
    PubMedGoogle Scholar
  • 42 Weale RA. Age and the transmittance of the human crystalline lens. J Physiol 1988; 395: 577-587
    CrossrefPubMedGoogle Scholar
  • 43 Kernt M, Hirneiss C, Neubauer AS. et al. Protektive Wirkung Blaulicht absorbierender IOLs auf das menschliche retinale Pigmentepithel. Ophthalmologe 2010; 107: 150-157
    CrossrefPubMedGoogle Scholar
  • 44 Schrage N. [Spectral transmission in blue filter intraocular lenses]. Ophthalmologe 2012; 109: 142-148
    CrossrefPubMedGoogle Scholar
  • 45 Downie LE, Busija L, Keller PR. Blue-light filtering intraocular lenses (IOLs) for protecting macular health. Cochrane Database Syst Rev 2018; (05) CD011977
    PubMedGoogle Scholar
  • 46 Davison JA, Patel AS, Cunha JP. et al. Recent studies provide an updated clinical perspective on blue light-filtering IOLs. Graefes Arch Clin Exp Ophthalmol 2011; 249: 957-968
    CrossrefPubMedGoogle Scholar
  • 47 Henderson BA, Grimes KJ. Blue-blocking IOLs: a complete review of the literature. Surv Ophthalmol 2010; 55: 284-289
    CrossrefPubMedGoogle Scholar
  • 48 Lai E, Levine B, Ciralsky J. Ultraviolet-blocking intraocular lenses: fact or fiction. Curr Opin Ophthalmol 2014; 25: 35-39
    CrossrefPubMedGoogle Scholar
  • 49 Wenzel M, Auffarth G, Scharrer A. et al. Outpatient and inpatient intraocular surgery 2013: Results of the survey by BDOC, BVA, DGII and DOG. Ophthalmo Surg 2014; 26: 171-182
    PubMedGoogle Scholar
  • 50 Wenzel M, Dick HB, Scharrer A. et al. Outpatient and inpatient intraocular surgery 2017: Results of the survey by BDOC, BVA, DGII and DOG. Ophthalmo Surg 2018; 30: 255-266
    PubMedGoogle Scholar
  • 51 Nishi T, Saeki K, Obayashi K. et al. The effect of blue-blocking intraocular lenses on circadian biological rhythm: protocol for a randomised controlled trial (CLOCK-IOL colour study). BMJ Open 2015; 5: e007930
    CrossrefPubMedGoogle Scholar
  • 52 Biesemeier A, Taubitz T, Julien S. et al. Choriocapillaris breakdown precedes retinal degeneration in age-related macular degeneration. Neurobiol Aging 2014; 35: 2562-2573
    CrossrefPubMedGoogle Scholar
  • 53 Brunner R, Widder RA, Fischer RA. et al. Clinical efficacy of haemorheological treatment using plasma exchange, selective adsorption and membrane differential filtration in maculopathy, retinal vein occlusion and uveal effusion syndrome. Transfus Sci 1996; 17: 493-498
    CrossrefPubMedGoogle Scholar
  • 54 Koss MJ, Kurz P, Tsobanelis T. et al. Prospective, randomized, controlled clinical study evaluating the efficacy of Rheopheresis for dry age-related macular degeneration. Dry AMD treatment with Rheopheresis Trial-ART. Graefes Arch Clin Exp Ophthalmol 2009; 247: 1297-1306
    CrossrefPubMedGoogle Scholar
  • 55 Brunner R, Widder RA, Walter P. et al. Influence of membrane differential filtration on the natural course of age-related macular degeneration: a randomized trial. Retina 2000; 20: 483-491
    PubMedGoogle Scholar
  • 56 Pulido JS, Winters JL, Boyer D. Preliminary analysis of the final multicenter investigation of rheopheresis for age related macular degeneration (AMD) trial (MIRA-1) results. Trans Am Ophthalmol Soc 2006; 104: 221-231
    PubMedGoogle Scholar